June 22, 2018 7:40am

Or not, after yesterday’s decline … an equity stress free weekend beckons

The oversold out-weigh the few overbought, though there’s still a question of value lost or to be gained?

 

When RMi is right more frequently  than not about “our” sector pricing and it is first in reporting price changing news; it just confirms why one should subscribe to understand how today’s pre-open indications shed light on share pricing!

 

U.S. stock index futures ticked higher ahead of Friday's open

Dow futures are UP +0.44% (+107 points) and NASDAQ futures are UP +0.31% (+23 points)

 

US stocks set for a positive open, as OPEC decision, trade fears weigh

European stocks higher as banks lead gains

Major Asian markets closed mixed; the U.S.-China trade dispute, along with other economic concerns, has made some cautious over the outlook for equity markets in Asia.

 

Data docket: the U.S. flash composite purchasing managers' index (PMI) figures, which is due out at 9:45 a.m. ET.

 

Henry’omics:

 

As another trading week draws to a close, market-watchers will likely be awaiting news coming out of the political, economic and commodity spheres. Markets around the globe have been on a rollercoaster ride this week as tensions surrounding a tit-for-tat trade dispute between the U.S. and China continue to escalate <CNBC>.

Because sector companies have less analyst coverage than larger companies there tends to be less volume and liquidity in small-caps.

As a result, from a risk perspective, a shorter-term view is needed …

 

Today’s indications:

  • The iShares Nasdaq Biotechnology (IBB) is NOT indicating in Friday’s pre-market;
  • The SPDR S&P Biotech ETF (XBI) is indicating a +0.32% upside in Friday’s pre-market;
  • The Health Care Select Sector SPDR ETF (XLV) is NOT indicating in Friday’s pre-open;
  • The iShares Russell 2000 (IWM) is indicating a +0.28% upside in Friday’s pre-open

 

From Thursday’s night’s newsletter: “home in the sector’s range follow-on lyrics …Oh give me a sector where the upside is sustainable, flows leisurely up in the market, where the graceful “swans” go gliding along, like an investor in a heavenly dream, Oh give me a home where the algorithms don’t roam!”

Of the 45 companies covered the 36 downside equities finished in a range of -$0.02 to -$2.96 followed by the biggest bottom of -$6.50 and $3.71 while the 9 upside equities oscillated from +$0.06 to $1.33 with toppers ranging from $6.67 to $4.25 with 0 flat closes.

Thursday’s decliners ranged from -0.18% <CRSP -$0.12 > to -17.25% < CLBS -$1.49> in 36 equities;

Thursday’s gainers ranged from +0.09% <BMRN +$0.09 > to +18.7% <SLDB +$6.67 > in 9 equities;

The iShares NASDAQ Biotechnology (IBB) was down -1.13% after Wednesday’s +1.66% after Tuesday’s +1.46% after Monday’s -0.75% and last Friday’s -0.11% - I am neutral as the week ends with an aggregate upside of +1.94%!

 

Companies in my headlights – It’s your decision; I provide the idea and context:

… There are day’s investors and traders should just step-away …

Stand down

If you had read Monday through Thursday night’s newsletters; you would be in a NO stress trading zone.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.